伊布替尼用于复发难治性变异型毛细胞白血病。 - Suppr

Suppr

超能文献

Ibrutinib for relapsed refractory hairy cell leukemia variant.

作者信息

Bohn Jan-Paul, Wanner David, Steurer Michael

机构信息

a Department of Internal Medicine V , Medical University of Innsbruck , Innsbruck , Austria.

出版信息

Leuk Lymphoma. 2017 May;58(5):1224-1226. doi: 10.1080/10428194.2016.1239262. Epub 2016 Oct 12.

DOI:10.1080/10428194.2016.1239262

PMID:27733095

Abstract

摘要

相似文献

Ibrutinib for relapsed refractory hairy cell leukemia variant.伊布替尼用于复发难治性变异型毛细胞白血病。

Leuk Lymphoma. 2017 May;58(5):1224-1226. doi: 10.1080/10428194.2016.1239262. Epub 2016 Oct 12.

Final analysis of a phase II study of ibrutinib in Japanese patients with relapsed/refractory mantle cell lymphoma.依鲁替尼用于日本复发/难治性套细胞淋巴瘤患者的II期研究的最终分析。

J Clin Exp Hematop. 2019;59(2):98-100. doi: 10.3960/jslrt.19006.

Outcomes of patients with relapsed/refractory double-expressor B-cell lymphoma treated with ibrutinib monotherapy.伊布替尼单药治疗复发/难治性双表达 B 细胞淋巴瘤患者的结局。

Blood Adv. 2019 Jan 22;3(2):132-135. doi: 10.1182/bloodadvances.2018026401.

High rates of proven invasive fungal disease with the use of ibrutinib monotherapy for relapsed or refractory chronic lymphocytic leukemia.在使用依鲁替尼单药治疗复发或难治性慢性淋巴细胞白血病时，侵袭性真菌病确诊率较高。

Leuk Lymphoma. 2019 Jun;60(6):1572-1575. doi: 10.1080/10428194.2018.1543884. Epub 2019 Jan 11.

Ibrutinib in relapsed hairy cell leukemia variant: A case report and review of the literature.伊布替尼治疗复发的多毛细胞白血病变异型：病例报告及文献复习。

Hematol Oncol. 2020 Dec;38(5):823-826. doi: 10.1002/hon.2810. Epub 2020 Oct 11.

Long-term Efficacy of Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia: Results of the Polish Adult Leukemia Study Group Observational Study.伊布替尼治疗复发/难治性慢性淋巴细胞白血病的长期疗效：波兰成人白血病研究组观察性研究结果。

Anticancer Res. 2020 Jul;40(7):4059-4066. doi: 10.21873/anticanres.14403.

Safety and efficacy analysis of long-term follow up real-world data with ibrutinib monotherapy in 58 patients with CLL treated in a single-center in Greece.在希腊的一家单中心，对 58 例接受伊布替尼单药治疗的 CLL 患者的长期真实世界数据进行安全性和疗效分析。

Leuk Lymphoma. 2019 Dec;60(12):2939-2945. doi: 10.1080/10428194.2019.1620944. Epub 2019 Jun 11.

Rapid onset of hemophagocytic lymphohistiocytosis in a patient with refractory chronic lymphocytic leukemia treated with ibrutinib.在接受依鲁替尼治疗的难治性慢性淋巴细胞白血病患者中迅速发生噬血细胞性淋巴组织细胞增生症。

Leuk Lymphoma. 2017 May;58(5):1258-1261. doi: 10.1080/10428194.2016.1243679. Epub 2016 Oct 17.

Zanubrutinib for the treatment of relapsed/refractory hairy cell leukemia.泽布替尼用于治疗复发/难治性毛细胞白血病。

Blood Adv. 2023 Jun 27;7(12):2884-2887. doi: 10.1182/bloodadvances.2022008990.

Vemurafenib for relapsed or refractory hairy-cell leukaemia.维莫非尼用于复发或难治性毛细胞白血病

Lancet Oncol. 2015 Oct;16(13):e484. doi: 10.1016/S1470-2045(15)00334-4. Epub 2015 Sep 18.

引用本文的文献

[Chinese guideline for diagnosis and treatment of hairy cell leukemia (2023)].[中国毛细胞白血病诊断与治疗指南（2023年）]

Zhonghua Xue Ye Xue Za Zhi. 2023 Dec 14;44(12):969-976. doi: 10.3760/cma.j.issn.0253-2727.2023.12.001.

Untangling hairy cell leukaemia (HCL) variant and other HCL-like disorders: Diagnosis and treatment.解开毛细胞白血病（HCL）变异型和其他类似 HCL 的疾病的谜团：诊断和治疗。

J Cell Mol Med. 2024 Feb;28(3):e18060. doi: 10.1111/jcmm.18060. Epub 2023 Dec 14.

Long term follow-up of refractory/relapsed hairy cell leukaemia patients treated with low-dose vemurafenib between 2013 and 2022 at the Department of Internal Medicine and Oncology, Semmelweis University.2013 年至 2022 年期间，在森梅威思大学内科和肿瘤学部，采用低剂量 vemurafenib 治疗难治/复发毛细胞白血病患者的长期随访结果。

Pathol Oncol Res. 2023 Nov 8;29:1611378. doi: 10.3389/pore.2023.1611378. eCollection 2023.

A Case of Hairy Cell Leukemia Variant: Literature Analysis With Focus on Unmet Needs.1例变异型毛细胞白血病：聚焦未满足需求的文献分析

Cureus. 2023 Oct 15;15(10):e47085. doi: 10.7759/cureus.47085. eCollection 2023 Oct.

The protective role of the microenvironment in hairy cell leukemia treatment: Facts and perspectives.微环境在毛细胞白血病治疗中的保护作用：事实与展望

Front Oncol. 2023 Mar 8;13:1122699. doi: 10.3389/fonc.2023.1122699. eCollection 2023.

Novel targeted treatments in hairy cell leukemia and other hairy cell-like disorders.毛细胞白血病及其他毛细胞样疾病的新型靶向治疗

Front Oncol. 2022 Dec 22;12:1068981. doi: 10.3389/fonc.2022.1068981. eCollection 2022.

Measurable residual disease in hairy cell leukemia: Technical considerations and clinical significance.毛细胞白血病中的可测量残留病：技术考量与临床意义

Front Oncol. 2022 Nov 10;12:976374. doi: 10.3389/fonc.2022.976374. eCollection 2022.

Updates in hairy cell leukemia (HCL) and variant-type HCL (HCL-V): rationale for targeted treatments with a focus on ibrutinib.毛细胞白血病（HCL）和变异型HCL（HCL-V）的进展：以依鲁替尼为重点的靶向治疗原理

Ther Adv Hematol. 2022 Apr 13;13:20406207221090886. doi: 10.1177/20406207221090886. eCollection 2022.

Hairy Cell Leukemia (HCL) and HCL Variant: Updates and Spotlights on Therapeutic Advances.毛细胞白血病（HCL）和 HCL 变异型：治疗进展的最新动态和亮点。

Curr Oncol Rep. 2022 Sep;24(9):1133-1143. doi: 10.1007/s11912-022-01285-1. Epub 2022 Apr 11.

Hairy Cell Leukemia Patients Have a Normal Life Expectancy-A 35-Year Single-Center Experience and Comparison with the General Population.毛细胞白血病患者的预期寿命正常——一项35年的单中心经验及与普通人群的比较。

Cancers (Basel). 2022 Feb 28;14(5):1242. doi: 10.3390/cancers14051242.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验